Skechers Is No Sketch Comedy


Skechers Is No Sketch Comedy

The footwear speedster gets tripped up after a disappointing quarter.

Skechers (NYSE:SKX) executed a 3-for-1 stock split on Oct. 16. Every shareholder received two additional shares with the stock dropping to a third of its previous price. It was a zero-sum game. There was an unintentional 3-for-2 stock split a week later after the athletic footwear maker posted disappointing quarterly results, but investors didn’t receive any more stock.

SkxYes, that’s a lighthearted way to describe the gloomy aftermath following Skechers’ rough quarter last week. The stock shed nearly a third of its value on Oct. 23 as growth decelerated, particularly at its domestic wholesale division that was rolling at a torrid pace before last week’s letdown. The market had been spoiled in previous quarters.

The stock’s 31.5% hit in a single day hurts — that’s no joking matter — but it’s hard for longtime investors to complain. The stock has nearly tripled since the start of last year even after accounting for the post-earnings hit.

Skechers is in a good place. Its brand isn’t as widely celebrated as Nike (NYSE:NKE), but it has grown to command half of the U.S. walking footwear market. It’s a distant second to Nike in the meatier realm of sports footwear, but at least it’s still a silver medalist.
Skechers has been getting aggressive with its celebrity endorsements, and unlike Nike that has historically flocked to top athletes, Skechers isn’t afraid to go pop with Demi Lovato, retired with Joe Montana, or even controversial with Pete Rose.

Even Ringo Starr has gotten in on the promotional fun with Skechers, promoting its Relaxed Fit shoes earlier this year. You’re unlikely to see Nike courting any 1960s rock stars anytime soon.
Skechers expects to have about 1,250 namesake retail stores around the world by the end of the year, and same-store sales have been strong. Comps clocked in at 10.6% last year, and have continued to hold up in the low double digits, even during last week’s poorly received third quarter where same-store sales rose a respectable 10.4%.

The fundamentals are still holding up their end of the bargain. The quarter that the market deemed horrific because it failed to live up to expectations still found Skechers clocking in with $856.2 million in revenue, 27% ahead of where it was a year earlier. Earnings from operations rose 29% to $95.6 million.


Skechers isn’t Nike, but it’s still growing a lot faster than the sultan of swoosh despite trading at a much lower trailing earnings multiple. Last week’s hit wasn’t pretty, but laces still come undone on good shoes.

Zalemark Holding Co. Enters into a $1 Million Equity Purchase Agreement with Kodiak Capital Group, LLC


Zalemark Holding Co. Enters into a $1 Million Equity Purchase Agreement with Kodiak Capital Group, LLC

Accesswire

Zalemark Holding Co. (ZMRK), today announced that it has entered into a $1 million common stock purchase agreement with Kodiak Capital Group, LLC, a Newport Beach, California-based institutional investor. Zalemark is an award winning product design, development, manufacturing and distribution Company that develops and markets strategic jewelry brands such as, Crayola(R) Fine Jewelry, Mars(R) M&M’s(R) Jewelry Brand, and Demeter(R) Fine Jewelry.

Zalemark has agreed to file a registration statement with the U.S. Securities and Exchange Commission covering the shares that may be issued to Kodiak under the terms of the common stock purchase agreement. After the SEC has declared the registration statement related to the transaction effective, Zalemark will have the right at its sole discretion over a period of one year to sell up to $1 million of common stock under the terms set forth in the agreement.

Proceeds from this transaction, if any, will be used to further develop and commercialize projects using Zalemark’s market expertise, extensive relationship capital and award winning industry performance.

“We are very excited about the opportunity to receive this capital infusion and the vote of confidence in our brand and business model by an investment group as renowned and successful in the consumer products space as Kodiak Capital,” commented Raymond Ruiz, Zalemark’s Chief Executive Officer. Scott Lopez, Kodiak Capital Group Advisory Board Member, said “We are equally pleased to be able to assist an industry innovator such as Zalemark as it moves forward with the commercialization and distribution of its world class products and market strategy.”

Aethlon Medical’s Biofiltration Platform Tackles Everything from Ebola to Cancer: CEO James Joyce


Aethlon Medical’s Biofiltration Platform Tackles Everything from Ebola to Cancer: CEO James Joyce

Source: Gail Dutton of The Life Sciences Report  (10/28/15)
James Joyce Aethlon Medical Inc. has pioneered a novel biofiltration platform that was used effectively against Ebola in 2014. Now this broad-spectrum platform is being tested against cancer and other life-threatening diseases. Aethlon CEO James “Jim” Joyce tells The Life Sciences Report how this device is helping transform modern healthcare.
cancerresearch580
The Life Sciences Report: Aethlon Medical Inc. (AEMD:NASDAQ) has developed a novel affinity biofiltration platform that removes disease-enabling particles from the bloodstream. How effective is it, and what makes it so effective?

James Joyce: At Aethlon Medical, we have established an expansive therapeutic platform that allows us to target a wide range of disease-promoting targets from the circulatory system. Our lead product, the Aethlon Hemopurifier, provides a clinical pathway into infectious disease and cancer. In 2014, TIME magazine named the device one of the 25 best inventions of the year and also one of the 11 most remarkable advances in healthcare.

In the case of the Hemopurifer, our device integrates advanced plasma membrane technology with an affinity lectin to reduce the presence of infectious disease and oncology targets without stripping out essential components required for health. The Hemopurifier is designed for use within the existing infrastructure of dialysis and continuous renal replacement therapy machines already located in hospitals and clinics worldwide.

“The Hemopurifer integrates advanced plasma membrane technology with an affinity lectin to reduce the presence of infectious disease and oncology targets without stripping out essential components required for health.”

In human studies, we’ve treated patients with HIV and hepatitis C. We also received a lot of attention in 2014 during the Ebola outbreak for our response in treating an Ebola patient at University Hospital Frankfurt. The patient was comatose, with multiple organ failure. At the time of treatment, he had approximately 400,000 copies per milliliter of Ebola virus in his blood. After the conclusion of a single six-and-a-half-hour Hemopurifier treatment, the viral load was next measured at approximately 1,000 copies per milliliter. Five days later, the virus was undetectable. The patient made a full recovery and returned home to his wife and children. This outcome was accomplished in the absence of antiviral drug therapy.

TLSR: How does this approach compare to drug-based therapies?

JJ: Using infectious viral pathogens as an example, the primary difference between our techniques and drug techniques is that antiviral drugs are designed primarily to inhibit replication of the virus, or to fuse to the virus to inhibit it from continuing to infect healthy cells. It’s an additive therapy.
We, in contrast, are extracting viral copies from the circulatory system in real time. Blood flows through our cartridge, which has an affinity to capture viruses and shed glycoproteins that, oftentimes, are immunosuppressive. So instead of an additive therapy, you could consider our device a selective subtracted therapy. We also have the unique ability to elute the biological fluid out of the cartridge after treatment for quantification. In one hepatitis C patient who was treated overseas, we determined that during one six-hour treatment we eliminated approximately 300 billion copies of hepatitis C virus during a single six-hour treatment.

TLSR: How long is a typical treatment session?

JJ: In clinical studies to date, treatments have ranged from four to six hours. The longest treatment was the Ebola patient.

TLSR: How does your system work, and does it have any competitors?

JJ: Historically, therapeutic biofiltration devices have mostly been limited to the indiscriminate removal of disease-causing particles by molecule size, through hollow fibers or porous beads. In our case, we’re combining the capabilities of hollow fibers with an affinity lectin that binds to a unique structure co-opted from the host cell during replication. This unique structure exists across different species, families, and strains of viral pathogens. That’s what gives us broad-spectrum capability.
In terms of other therapeutic biofiltration devices, we aren’t aware of any competitors that combine a simultaneous affinity and separation mechanism.

TLSR: What are the potential applications?

JJ: In terms of infectious viral pathogens, people are often surprised to learn that more than 300 viral pathogens are known to be infectious to humans. Of those viruses, only nine are addressed with approved antiviral drug therapies. There is a tremendous need for countermeasures against Category A pathogens, which are considered bioterror or pandemic threats. In those cases, we are working to tip the balance in favor of the immune system, much like we did with the Ebola patient, to rapidly reduce viral load and allow the patient’s immune system a greater opportunity to overcome infection.

“In terms of other therapeutic biofiltration devices, we aren’t aware of any competitors that combine a simultaneous affinity and separation mechanism.”

For chronic viral conditions such as HIV or hepatitis C, we look at the ability to address mutant or drug-resistant virus strains that cause people to fail their antiviral drug therapies. Here, we can work in conjunction with drug therapies, or as a potential monotherapy for people who have become fully drug resistant.

TLSR: Where do you envision treatment occurring?

JJ: Initially, we envision that our therapies would be available in hospitals and dialysis clinics. As we expand into oncology indications, we would like to have a portable instrument that would allow our technology to be easily delivered on an outpatient basis, in physicians’ offices.

TLSR: How do you envision the Aethlon pipeline building out?

JJ: Right now, we have the ability to interchange affinity agents to create capabilities against different indications. Today, our primary focus is on advancing our technology against viral pathogens and expanding the use of the Hemopurifier into oncology.

We also have a U.S. Department of Defense contract with the Defense Advanced Research Projects Agency (DARPA), in which we’re utilizing our device platform to create new therapies for sepsis. Those are our two primary areas of focus.

Long term, we are very excited about the discovery that our Hemopurifier can capture tumor-secreted exosomes.

When we first started looking at tumor-secreted exosomes, the medical community consensus was that they were just cellular debris with no biological function. We believed that these particles were immunosuppressants. Today, it’s well understood that tumor-secreted exosomes are, in fact, immunosuppressive, and that they also play a much larger role in cancer progression. That role is related to the fact that exosomes are seeds that facilitate the creation of metastases, and they transport other particles that lead to cancer progression. Consequently, the elimination of circulating tumor-secreted exosomes would address a significant unmet medical need in cancer care.

“Our primary focus is on advancing our technology against viral pathogens and expanding the use of the Hemopurifier into oncology.”

Researchers have also reported that tumor-secreted exosomes trigger apoptosis (programmed cell death) of immune cells and contribute to drug and chemotherapy resistance. It’s also important to recognize that circulating tumor-exosome load correlates to the stage of cancer.

We believe that eliminating circulating tumor-secreted exosomes, in combination with emerging immuno-oncology drugs, should be clinically tested—especially considering the possibility that our device could combine with other therapies to improve treatment outcomes without adding drug toxicity.

TLSR: How will Aethlon make an impact in the oncology sector?

JJ: We believe the elimination of tumor-secreted exosomes could unlock the capability of emerging immuno-oncology drugs. What better way to improve the immune system’s ability to combat cancer than to have a device that targets exosome-related immune suppression working in tandem with immuno-oncology drugs designed to stimulate the ability of the immune system to combat cancer?

TLSR: Are you working with any other companies to do that?

JJ: We currently are conducting in vitro validation studies, as well as a study at the University of California, Irvine. We’re recruiting patients with nine different types of cancer to help us determine which indication we should first pursue.

TLSR: What are the regulatory hurdles? Where are you in the approval process?

JJ: We have conducted multiple studies overseas, which contributed to our obtaining approval for an investigational device exemption (IDE) by the FDA. In the U.S., we are actively moving forward to conduct a 10-patient feasibility study at DaVita Med Center Dialysis in Houston, Texas. This study provides a gateway into pivotal studies for infectious viral pathogens, where it is feasible to conduct controlled efficacy studies. The study protocol is quite similar to a protocol we successfully conducted overseas. We also hope to leverage this feasibility into future oncology indications.

TLSR: You mentioned the DARPA sepsis program. Tell me about that. How is it evolving?

JJ: We are a participant in DARPA’s Dialysis-Like Therapeutics (DLT) team program. The goal of the DLT program is to create a sepsis treatment device and then submit an IDE to the division of the Center for Devices and Radiological Health at the FDA, as a means to initiate human clinical studies. The DLT team has done tremendous work in advancing instrument designs, as well as in discovering therapeutic biofiltration mechanisms that could be beneficial in treating sepsis patients.

TLSR: Let’s talk about finances. Aethlon was listed on NASDAQ earlier this year, receiving a $6 million injection of capital. How do you plan to use these funds?

JJ: The uplisting to NASDAQ was of significant importance as it provides us with access to the broader capital markets going forward. The proceeds are primarily directed toward clinical progression.

“We believe the elimination of tumor-secreted exosomes could unlock the capability of emerging immuno-oncology drugs.”

Based on the magnitude of the underlying markets we are targeting, we believe that successful clinical progression would drive stakeholder value and allow us to access the capital markets in the future on a less dilutive basis, as compared to our options prior to listing on NASDAQ.

TLSR: Why is your management team uniquely suited to take this company forward?

JJ: We have evolved our technology from a theoretical concept into early R&D studies, then into animal studies, and then into multiple human studies, which now allows us the opportunity to work with the FDA to clinically advance our vision in the United States. As our product is a first-in-class therapy, our small team has an unrivaled understanding of our technology and the industry space.
In fact, our capabilities to selectively target disease-promoting factors from blood led to the launch of a majority-owned subsidiary, Exosome Sciences Inc. Though not our core focus, Exosome Sciences is working to expand the application of some of our affinity binding techniques into the diagnostic field.

Our methods are being tested in the Diagnosing and Evaluating Traumatic Encephalopathy Using Clinical Tests (DETECT) study, which is managed by Boston University’s Chronic Traumatic Encephalopathy (CTE) Center. CTE is a chronic neurological condition associated with sub-concussive blows to the head. It’s best known from a media standpoint for its prevalence in former NFL players.

“The uplisting to NASDAQ was of significant importance as it provides us with access to the broader capital markets going forward.”

Presently, CTE can only be diagnosed postmortem, through autopsy. There is no blood-based test to identify the disease. The Veterans Administration and our collaborators at Boston University have identified CTE in 87 of 91 brains of former NFL players that were examined post-autopsy.

The goal of the DETECT study is to discover a biomarker that could identify CTE while people are alive. We have discovered an exosome-based particle, which we call a Tausome, that we believe correlates very closely with cognitive decline. In our initial studies, we have observed that Tausome levels in former NFL players are significantly higher than that of control subjects. A manuscript that details our findings is pending publication.

TLSR: What can we expect from Aethlon near term, and five years on?

JJ: In the near-term, we need to accelerate the pace of our IDE feasibility study. We are now completing the transition of our study principal investigator, as previously disclosed. We have also been quite busy in the interim, as we have worked to improve the quality assurance, quality control, and document control functions that underlie the manufacturing of our technology. We have also been advancing methodologies through collaborations that should allow for low-cost, large-scale production of the affinity lectin that we immobilize within our Hemopurifier. We’ve been quietly building the internal engine of the company.

Now we need to move forward on the clinical side, and then leverage our outcomes into pivotal studies against chronic viral pathogens, where it is feasible to conduct controlled clinical studies. We will pursue humanitarian pathways for high-threat viral pathogens that are not treatable with antiviral drug therapies.

Parallel to our viral endeavors, we need to leverage our opportunity in the oncology space, which I believe is an untapped value driver for our company long term.

Based on our novel device mechanism and the size of underlying market opportunities, successful clinical progression might also trigger the interest of large players in the infectious disease and oncology fields.

TLSR: You just mentioned the importance of larger players. Are you looking to perhaps license the technology, develop it yourself, or partner with another company?

JJ: At this point in time, the Hemopurifier technology is developed. We have a lot of clinical experience abroad that we’re working to replicate here in the U.S.

In terms of other development opportunities, we eventually may want to partner with others to immobilize a variety of affinity agents to advance selective extracorporeal cocktail therapies to address unique yet hard-to-treat disease conditions.

As a medical device developer we don’t have the same overall clinical challenges as biologic drug developers, so we’re not forced to partner or license our technology to advance. What we really need to focus on is clinically progressing our technology and showing that it’s not just safe, but also can provide patient benefit in large disease conditions.

TLSR: Is there anything else that you’d like investors to know?

JJ: To summarize, we have an expansive therapeutic device platform. Our lead product, the Hemopurifier, provides a clinical pathway into both infectious disease and cancer. It has proven, broad-spectrum capabilities against viral pathogens, and could be an untapped value driver based on the discovery that our Hemopurifier can also capture cancer-promoting exosomes.
In terms of our DARPA DLT team, we hope to have a sepsis treatment candidate ready for an IDE submission in the coming year.

Then, on the diagnostic front, we have a manuscript pending publication related to the first blood-based biomarker candidate to identify and monitor CTE in living individuals.
TLSR: Jim, thank you very much.

James A. Joyce is the founder, chairman and CEO of Aethlon Medical. Under his leadership, Aethlon has transformed the concept of a selective therapeutic filtration device (the Aethlon Hemopurifier) into the reality of treating patients in a clinical setting, with follow-on research validating the ability of the Hemopurifier to capture a broad-spectrum of bioterror and pandemic threats as well as immunosuppressive cancer exosomes. Joyce has originated numerous collaborative relationships with government and non-government research organizations, has authored supporting publications and reports, and raised capital resources to support the mission of Aethlon Medical. He has represented the company on CNN, NBC, ABC and other media outlets, and has testified before Congress on issues related to Project BioShield legislation and the deployment of the Aethlon Hemopurifier as a countermeasure against biological weapons. In May 2011, the company introduced the Aethlon ADAPT system, a device platform that converges affinity drug agents with plasma membrane technology to create new candidate therapies against life-threatening disease conditions. From February 1993 until founding Aethlon Medical, Joyce was CEO of James Joyce & Associates. Previously, he was founder and CEO of Mission Labs Inc., was a principal at London Zurich Securities Inc., and was a member of the Denver Broncos Football Club of the National Football League. Joyce is a graduate of the University of Maryland.

New Global Energy, Inc. is Aquaculture, Agriculture and Health & Wellness


New Global Energy, Inc. (NGEY) (“NGEY”) (“the Company”), a public company focused on Aqua-Farming, Agriculture, and Health & Wellness, announced today that it has launched the tilapia spawning season at its farm in California’s Coachella Valley with a record number of fish. New financing commitments from outside investors mean the coming year should prove to be record setting in terms of the number of sustainable fish grown and ultimately sold on the company’s farm.
October is a critical month for planning and preparation since fish are seasonal and the new fingerlings will reach sufficient size from October through mid-November before temperature drops and will survive the mildly cold months of December and January. To help insure strong growth and because consumers increasingly demand healthy seafood, New Global feeds its fish a formula that is free of GMOs, antibiotics and chemicals and which includes the perfect blend of the superfood Moringa, nutrient rich algae, and a proprietary blend of other ingredients.

“New Global Energy is at the forefront of developing and implementing the most advanced, sustainable, ecologically sound methods of producing clean, quality seafood. Sustainable features of our farm include the use of solar electricity, nutrient dense fish food, water recirculation through ponds that contain plants that clean the water for re-use, and the nutrient rich fish pond water that is also used to irrigate the Moringa used for the fish feed,” said New Global Energy’s CEO Perry West.

Tilapia is an ideal fish due to its excellent taste yet less than 10 percent of tilapia consumed in the United States is farmed domestically. According to the National Fisheries Institute, tilapia now ranks fourth on its ‘Top Ten’ list of the most consumed fish and seafood in the United States. During 2010, the average consumption of tilapia was nearly 1.5 pounds, up from 1.2 pounds per person the previous year. A recent United Nations study predicts that unless something changes, most commercial fisheries will be producing less than 10% of their one time potential by the middle of this century. The United States imports about 86 percent of its seafood and only half is wild caught. The global demand for farm-raised fish is expected to double by 2030.

About New Global Energy, Inc. 

New Global Energy Inc. (NGEY) is a public company focused internal growth and growth through the acquisition of high-growth firms, assets and properties in the Green market space; industry segments include sustainable agriculture, aquaculture, solar, biofuels and carbon credits. Management is targeting growth stage assets, operations and companies that possess proprietary market edge and demonstrate solid opportunity to scale their business. We expect to pursue special opportunities that are anticipated to accelerate shareholder value by consolidating certain tiers of the $5 Trillion per year fragmented Green and Renewable Energy industry.

New Global currently has interests in agriculture, aquaculture and solar power operations in Southern California and is assisting in improving its control of key factors affecting production cost by vertically integrating into feed production and electricity production, (solar), and by delivering direct to market.

Through its aquaculture business, New Global is targeting the acquisition of additional farmland which provides current income as well as the other benefits of hard assets. The Company believes that farmland will benefit from the increase in demand for grain, environmental demand for alternative energy, and the impact of globalization.

About AquaFarming Tech 

Aqua Farming Tech http://www.aquafarmingtech.com is a wholly owned subsidiary of New Global Energy Inc. and a leader in the seafood industry that has been farming tilapia in the Coachella Valley since September 1993. Its state of the art aquaculture operations are conducted from two farms encompassing 120 acres. As an industry innovator, Aqua Farming Tech was the first farm with more than 60 tanks, one of the first farms to build above ground cement tanks, the first farm to utilize a mechanical aerator to improve the oxygenation of its water, the first farm to develop and implement a method of recycling its water and the first farm to generate a significant percentage of its power from solar and the first farm to self-manufacture its own feed. Aqua Farming Tech is a fish farm/hatchery founded and run by Rocky French that is dedicated to producing the purest, best tasting seafood anywhere.

Walgreens Boots Alliance near deal to buy Rite Aid – WSJ


Walgreens Boots Alliance near deal to buy Rite Aid – WSJ

Oct 27 (Reuters) – Drugstore operator Walgreens Boots Alliance Inc is in advanced talks to buy smaller rival Rite Aid Corp, the Wall Street Journal reported, citing people familiar with the matter.
A deal is expected to be announced by Wednesday, the newspaper said. (http://on.wsj.com/1POU6xb)
Rite Aid’s shares were up 42 percent at $8.58. Walgreen’s shares were up 4.2 percent at $93.46.

NXT-ID, Inc. CEO Participating in Nasdaq Closing Bell Ceremony at Money 20/20


NXT-ID, Inc. CEO Participating in Nasdaq Closing Bell Ceremony at Money 20/20

PR Newswire

OXFORD, Connecticut, October 27, 2015 /PRNewswire/ —

NXT-ID, Inc. (NXTD) CEO Gino Pereira will be participating at the Nasdaq Closing Bell Ceremony today at Money 20/20. The ceremony will be streamed live and can be watched at https://new.livestream.com/nasdaq/live or on television networks like CNBC, Fox Business or Bloomberg right at 4:00pm ET when the markets close.

NXT-ID, Inc. is demonstrating Wocket® Smart Wallet at the conference taking place at the Venetian Resort in Las Vegas, Nevada, October 25th to October 28th, 2015.

Wocket® is the smartest wallet you’ll ever own. Designed to protect your identity and replace your old wallet, simply swipe and save your cards into Wocket once and they are immediately secured with pin and biometric voice print technology.  Without ever needing a smartphone, you can choose a card from the touch screen and Wocket programs its single, smart card (Wocket Card) to match your selection. From there, you just swipe as you normally would virtually anywhere that credit cards are accepted today.

All your credit, debit, loyalty, gift, ID, membership, insurance, medical information, passwords, and other information can be protected on Wocket®.

Buy Wocket® at http://www.wocketwallet.com
See the full Wocket® FAQ at: http://wocketwallet.com/pages/faq
Product images are available for media at: http://press.nxt-id.com

About NXT-ID Inc. – Mobile Security for a Mobile World: (NXTD)  

NXT-ID, Inc.’s innovative MobileBio® solution mitigates consumer risks associated with mobile computing, m-commerce and smart OS-enabled devices. The company is focused on the growing m-commerce market, launching its innovative MobileBio® suite of biometric solutions that secure consumers’ mobile platforms led by Wocket®; a next generation smart wallet designed to replace all the cards in your wallet, no smart phone required. Wocket was recognized as one of the top technology products at CES 2015 by multiple media outlets including Wired.com. The Wocket works most anywhere credit cards are accepted and only works with your biometric stamp of approval or passcode. http://www.wocketwallet.com/

NXT-ID’s wholly owned subsidiary, 3D-ID LLC, is engaged in biometric identification and has 22 licensed patents in the field of 3D facial recognition http://www.nxt-id.com/, http://3d-id.net/
About Money20/20 (http://www.money2020.com/)

As the industry’s primetime conference and trade show, Money20/20 delivers the biggest scale, best audience and most engaging event. Money20/20 is the largest global event focused on payments and financial services innovation for connected commerce at the intersection of mobile, retail, marketing services, data and technology. With 10,000+ attendees, including more than 1,000+ CEOs, from 3,000+ companies and 75 countries, expected at our 2015 U.S. event, Money20/20 is critical to realizing the vision of disruptive ways in which consumers and businesses manage, spend and borrow money.

Ford misses on earnings, but the third quarter was its best ever in North America


Ford misses on earnings, but the third quarter was its best ever in North America

Business Insider

Ford


Ford reported third quarter earnings on Tuesday.

They were slightly lower than analysts expectations. The company earned $0.45 per share. Analysts surveyed by Bloomberg were expecting $0.47 per share.

Revenue was $38.1 billion.

Higher taxes cut into Ford’s profit for the quarter, Reuters reported.

Ford posted its best-ever quarter in North America, driven by sales of the F-150 full-size pickup, which was redesigned to use more lightweight aluminum in its construction.

There were issues with supply of the new truck that weighed on Ford sales earlier in the year. But in the third quarter, the car maker delivered over 207,000 pickups.
The auto market in the US has been booming. It’s on a pace to see 17.5 million in new vehicle sales by December.
“We are delivering a breakthrough year,” said CEO Mark Fields in a statement.

Skechers Is Even More Attractive After Earnings Release


Summary

The global footwear industry will grow at a CAGR of 1.72% by 2020.
Skechers expects to double its business over the next five years.
Skechers GoWalk should keep adding more sales in the coming quarters.

While investors were enjoying the tech rally last week, the shoe stocks fell sharply after earnings announcement of Under Armour (NYSE:UA) and revenue miss of Skechers USA (NYSE:SKX). Although Skechers delivered strong earnings growth in the latest quarter, the soft sector outlook and thus ability to maintain a high double-digit top-line growth in a very competitive industry is now a major concern. Resultantly, Skechers plunged due to deteriorated investor sentiment and lost 31.50% value in one day.

Skechers share price is on a consistent rise since 2014 driven by strong top as well as bottom-line growth. After the crash, Skechers is still outperformer, up 75% YTD. Skechers results were not that bad, and this dip in price is an ideal opportunity for long-term investor.


Source: NASDAQ

The second Largest Player – Ahead of expectations

The global footwear industry value stood at $198.8 billion in 2014 while volumetric sales stood at 9990.7 million units. The industry sales are likely to reach $220.2 billion with 10,974.0 million units by 2020, depicting a value CAGR of 1.72% and volume CAGR of 1.58%. While Nike (NYSE:NKE) is the largest athletic footwear company in the U.S. with a market share of 62%, Skechers holds the second position with 5% market share.

The currency headwind and one-off expenses, which includes increased legal expenses due to a legal settlement and pending litigation and increased deferred rent expenses related to new Fifth Avenue location, negatively impacted the earnings. Thus, excluding that impact of $0.15 per share the diluted earnings per share of Skechers increase to $0.58, a beat of $0.03 per share. This also translates into a massive jump of 76% in adjusted earnings.

The Slowdown

Skechers results were not that bad. The company recorded 27% growth in top-line as it generated sales revenue of $856.2 million, but missed the estimate of $876.5 million. The currency headwind and slow acceleration in domestic sales negatively impacted the revenue growth momentum. Skechers is aggressively marketing new innovative products to maintain the growth. The launch of co-branded Star Wars Skechers footwear for Boys and celebrity endorsement, which include Demi Lovato and Ringo Starr, will support the sales in the coming quarters, particular holiday season.
The trend is declining as evident from the fact that first and second quarter 2015 sales increased by 40.5% and 36.4%, respectively. The credit rating agency has changed the outlook for the U.S. apparel and footwear industry from positive to stable. Moody’s expects the U.S. apparel and footwear industry revenue to grow 4% – 6% by 2016. The slowdown in sales growth is attributable to small base effect and penetration level into the certain market category where strong competition from Nike, Adidas (OTCQX:ADDYY) and Under Armour would restrict the top-line growth.
The domestic wholesale business, which accounted for 42% of total sales, delivered just 12% increase during the third quarter as compared to 30% in the previous quarter. This decline suggests that the strategic shift into low-priced sports shoes may not be sustainable over the long run. On the other hand, the strong presence in walking shoe category with Skechers GoWalk should keep adding more sales in the coming quarters.

Expansion To Deliver More Growth

While growth in the domestic market is slow, betting on international markets will help Skechers to achieve its long-term growth target. During the third quarter, international wholesale business accounted for 30.2% of total sales, up from previous year contribution of 25.7%. The increasing contribution from international markets is in-line with the company strategy to earn roughly half of total sales from outside the domestic market by 2020. So far, this strategy is working well for Skechers and international wholesale business delivered 53% increase in sales, which included strong double-digit gains in Europe and triple-digit growth in China and the Middle East. China and the Middle East will should the primary target markets outside the U.S. as pricing and brand appeals of Skechers fit in those markets.

In the meanwhile, the operating strategy of Skechers is very convincing. The joint ventures, franchisees, and distributors’ network helped Skechers to expand successfully in the domestic as well as international markets. Thus, increasing the store base to over 1,280 by the end of the year will add quick numbers to the top-line. Moreover, the focus on launching new innovative products across all the categories while improving distribution channels should boost sales and profitability. In addition to that, Skechers must overcome its weakness in direct-to-consumer sales to improve the profit margins.

Nike Is Eyeing $50 Billion In Sales – Skechers To Double The Business

Nike dominates the athletic footwear industry and it is very hard for a company like Skechers to compete with Nike. The unmatchable innovative, a strong brand name across the globe and top-class athlete name attached to Nike makes the company hard to beat. Nike is growing at a very decent and consistent pace. Nike is eyeing $50 billion in annual sales revenue by 2020, up from current $30.6 billion. This means Nike is targeting a CAGR of 13% over the next five years, which is pretty achievable as Nike witnessed 10% growth in the fiscal year 2015. Nike’s main bet is women category, the business Nike intends to double over the next five years.

On the other hand, Skechers also expects to double its business over the next five years. Nike is premium athletic brand whereas Skechers is a low-priced brand. Both companies are successful in their strategy, and I think Skechers will continue to focus certain class of customers rather than aggressively competing with Nike. Moreover, the increasing buying of athletic-styled clothes and shoes for everyday wear will benefit both companies.

Final Thoughts

Skechers is primarily focused on comfort and style to target women, young girls and kids. Skechers is targeting younger girls with pop singers Demi Lovato and Meghan Trainor as endorsers. Moreover, with the development of new innovative products, brand awareness in the international markets, and aggressive expansion will have a positive impact on growth momentum across three main business channels in the future. Although there is a risk of a slowdown in top-line growth, the international markets and marketing arrangement will continue to support a high double-digit sales growth for a longer run.

As the earnings outlook is intact, the valuation of the company is looking more attractive and the dip is an ideal opportunity to buy Skechers for long-term investment. The stock is trading at forward PE of 14.79x, very low multiple for a growth stock which is delivering robust sales as well as earnings growth. Thus despite a slight bounce back, Skechers offers a hefty upside potential of roughly 42% at an average target price of $47.08.

Brokerages Set Horizon Pharma PLC PT at $37.88 (NASDAQ:HZNP)


Brokerages Set Horizon Pharma PLC PT at $37.88 (NASDAQ:HZNP)

 :HZNP) has received a consensus recommendation

Horizon Pharma PLC (NASDAQof “Buy” from the eleven research firms that are presently covering the stock, MarketBeat.Com reports. Two analysts have rated the stock with a hold rating and nine have issued a buy rating on the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $37.88.

Shares of Horizon Pharma PLC (NASDAQ:HZNP) opened at 17.06 on Thursday. The stock’s market capitalization is $2.72 billion. The company’s 50-day moving average price is $22.48 and its 200 day moving average price is $29.63. Horizon Pharma PLC has a one year low of $11.87 and a one year high of $39.49.

Horizon Pharma PLC (NASDAQ:HZNP) last posted its quarterly earnings data on Friday, August 7th. The biopharmaceutical company reported $0.39 EPS for the quarter, topping the consensus estimate of $0.32 by $0.07. During the same period last year, the business earned $0.21 EPS. The company earned $172.80 million during the quarter, compared to the consensus estimate of $156.41 million. The firm’s quarterly revenue was up 161.4% compared to the same quarter last year. Analysts anticipate that Horizon Pharma PLC will post $1.39 EPS for the current year.

In other Horizon Pharma PLC news, EVP Jeffrey W. Sherman sold 7,750 shares of Horizon Pharma PLC stock in a transaction that occurred on Monday, September 21st. The shares were sold at an average price of $31.78, for a total transaction of $246,295.00. Following the completion of the sale, the executive vice president now directly owns 105,132 shares in the company, valued at approximately $3,341,094.96. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

HZNP has been the topic of several recent research reports. Leerink Swann reiterated a “positive” rating and set a $37.00 target price on shares of Horizon Pharma PLC in a research report on Tuesday, July 7th. Brean Capital restated a “buy” rating and set a $40.00 price target (up previously from $33.00) on shares of Horizon Pharma PLC in a report on Wednesday, July 8th. Piper Jaffray reiterated a “positive” rating and issued a $38.00 target price on shares of Horizon Pharma PLC in a report on Tuesday, July 14th. Guggenheim restated a “buy” rating on shares of Horizon Pharma PLC in a report on Monday, August 3rd. Finally, JMP Securities started coverage on Horizon Pharma PLC in a research report on Wednesday, September 9th. They set an “outperform” rating and a $39.00 target price for the company.

Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a specialty biopharmaceutical firm focused on identifying, developing, acquiring or in- commercializing and licensing differentiated products that address unmet medical needs. The Company markets a portfolio of products in orphan and arthritis, inflammation disorders. The Company’s the United States advertised products are ACTIMMUNE (NASDAQ:HZNP), DUEXIS (ibuprofen/famotidine), PENNSAID (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%), RAYOS (prednisone) delayed-release pills and VIMOVO (naproxen/esomeprazole magnesium). The Company developed DUEXIS and RAYOS/LODOTRA, gets the Usa rights to VIMOVO, gets the Usa rights and has the Usa rights to PENNSAID 2%.

Rocky Mountain High Brands, Inc. (RMHB) to Produce New ‘Snow Flake’ Graphic Cans This Week


Rocky Mountain High Brands, Inc. (RMHB) to Produce New ‘Snow Flake’ Graphic Cans This Week

Marketwired

DALLAS, TX–(Marketwired – Oct 26, 2015) –

Rocky Mountain High Brands, Inc. (OTC PINK: RMHB) announced today that the new ‘Snow Flake’ graphic cans of Rocky Mountain High beverages will be produced this week. The new graphic design is targeted specifically for large National / Regional retail accounts. The production run will also feature the introduction of a white can with colored mountains for all five (5) products, an infusion of 100 mg of hempseed extract in each can versus the previous 50 mg, the brand new 15 calorie Mango Energy drink sweetened with stevia and agave nectar, and now both energy drinks will contain 120 mg of caffeine.

The New Mango Snow Flake Can is viewable on the Products page: http://rockymountainhighbrands.com/products/

“A record breaking expanded production run of 96,000 cases will be produced this week,” said Tom Shuman, President and CEO of RMHB. “The production run will now allow us to move into Phase 2 of our marketing strategy. Phase 1 was to change the corporate name from Totally Hemp Crazy to Rocky Mountain High Brands to provide the company easier access to larger corporate retail accounts, and to build brand equity in one brand name — Rocky Mountain High. The second part of the plan is to introduce the new Snow Flake can design to Regional and National Accounts in an effort to expand our original target market beyond just 18-34 year olds, and to provide all retailers with a consumer friendly can that will experience less resistance to ‘family oriented’ retail operations that sell products with a more diverse age demographic. Rocky Mountain High will continue to produce the ‘Hemp Leaf’ can, and carry two separate inventories of our products, so as to also satisfy those retailers that wish to portray a bit more ‘edgy’ version of our brand and beverages. We also plan to increase the size of our can to 16 ounces in the not too distant future.”

Todd Kornely, Vice President of Sales, stated, “Producing an alternative can design to increase distribution, sales and market share is straight from the playbook of the ‘Big Soda Companies’ like Coke, Pepsi and Dr Pepper. We have already received pre-orders from a number of our distributors for the ‘Snow Flake’ can graphic; stay tuned as we will be making announcements very soon regarding new distribution partners and retailers, as soon as they receive the new product and are able to stock them on store shelves. Due to pre-orders for the new ‘family-friendly’ can design, we anticipate the current production run will sell out in record time.”

RMHB Founder, Jerry Grisaffi, was quoted as saying, “These are exciting times for the company. All of the new production will include a 100% increase of hemp seed extract. The energy drink products will now feature 120 mg of caffeine, the addition of a new can graphic to appeal to a new and larger demographic consumer and retailer group, plus the development of additional products that we will be adding very soon to our hemp-infused portfolio.”

For Rocky Mountain High Distribution Contact:
Todd Kornely:
(972) 804-9620
todd@rockymountainhighbrands.com

For Rocky Mountain High CBD Opportunities:
Jason Robillard:
(303) 665-5828
jason@rockymountainhighbrands.com

About Rocky Mountain High Brands, Inc.: 

Our Mission is to increase shareholder value by being the premier Hemp-Infused Beverage Company in the World. RMHB formerly traded as THCZ.
Visit our Corporate Website at: http://www.RockyMountainHighBrands.com
Investors Hangout is the only authorized Investors blog page for Rocky Mountain High Brands, Inc.